about
Site-specific functionalization of proteins and their applications to therapeutic antibodiesMultivalent Aptamers: Versatile Tools for Diagnostic and Therapeutic ApplicationsExtremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein ScaffoldA hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyCombinatorial peptide libraries: mining for cell-binding peptides.High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.Construction and development of a mammalian cell-based full-length antibody display library for targeting hepatocellular carcinoma.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Optical imaging in vivo with a focus on paediatric disease: technical progress, current preclinical and clinical applications and future perspectivesStructure-guided U2AF65 variant improves recognition and splicing of a defective pre-mRNA.Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumorsCancer radioimmunotherapy.Drug waste minimization as an effective strategy of cost-containment in oncology.Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachChallenges in design and characterization of ligand-targeted drug delivery systems.Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingEvaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.High cell-surface density of HER2 deforms cell membranesCross-arm binding efficiency of an EGFR x c-Met bispecific antibody.Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlationBiodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.Cost savings from dose rounding of biologic anticancer agents in adults.Antibody vectors for imaging.Biotechnological applications of recombinant single-domain antibody fragments.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Pretargeted molecular imaging and radioimmunotherapy.Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.In vivo applications of magnetic nanoparticle hyperthermia.The application of monoclonal antibodies in cancer diagnosis.Agents described in the Molecular Imaging and Contrast Agent Database for imaging carbonic anhydrase IX expression.Nanobody-based cancer therapy of solid tumors.On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.Monoclonal antibodies: technologies for early discovery and engineering.New Neurotensin analogue radiolabeled by (99m) Technetium as a potential agent for tumor identification.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets99m Tc-anti-epidermal growth factor receptor nanobody for tumor imaging.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoImpact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
P2860
Q26830699-C6D137AE-50E7-4FBB-9FA8-BDA3F19023B3Q28073119-1B6C1AA4-6CE8-49C0-95E7-DDBE04C89973Q28547051-C9782E6A-386A-4CFF-B40D-B52A50EDDD63Q30420026-6A95CAF3-96C3-473E-A658-3362805F37C6Q31144876-8339FBDA-AF5D-4150-88F0-AF4C16001211Q33896979-EB60A572-A0AB-46E5-BA75-BADDE417A11FQ34330468-802CD359-DEAB-40D8-A97F-DBEC228D9CF8Q34447986-6D9BAD52-7B2C-494F-AD7F-7E0ED1C1B871Q34544842-2884ED89-0E1A-4062-AFA7-6720F90FB169Q34709228-7C8031DC-7949-4CC0-A845-67B5EB5B51BEQ34802043-A6238EBA-4828-4769-8F6D-9B63A03F78E1Q35070045-03D8CA59-313B-42C0-8996-07F3D0E13A60Q35089146-FDFCCBA3-F6D9-4273-AFF1-D2261BF5D845Q35764163-964DB065-0A19-4CBF-8249-759511AA9B75Q36346851-BA062FBF-AB02-423D-AB77-5C7261B1AB95Q36491493-7AA229B1-D132-4929-9845-0772868362FEQ36498107-06A0050D-77A5-428E-ACF4-758802A00440Q37257182-BBAB8689-1460-4D49-8C2D-7C5FF61D1427Q37287006-44E5082D-298D-4B84-86B0-E1AE90E7AEBEQ37572883-1DEE4C22-4380-475E-AD9E-1B0ADF5B8A4FQ37635011-4D36880B-A2D2-4427-94E9-4408A2ADBBADQ37684670-34681624-94BC-4F88-92AC-F60354C5A710Q37717856-7DA08715-6533-4703-8E59-947E6C8A5001Q37720850-7C9A20FD-3910-48CA-A6B1-09279C0381C9Q37887077-D6328FC2-4900-472D-857E-6365DCA177C4Q38017581-24BEDCB3-C4FF-4E02-81E9-105FD4581FACQ38022016-87A582A4-26B0-4E09-A877-C833E1A06D2DQ38075043-B7866A2F-6D25-466E-B4C7-510E15534F68Q38161993-6AD6DF86-CEC0-4AD3-A119-252752888B14Q38168870-32159699-6519-403C-8DE6-9E83A30E4149Q38186073-BE839099-DB63-4860-9438-C99E266FF370Q38322471-CFEE78E7-AF7B-4071-AE02-C47647B892C9Q38545579-5394C092-2ED9-4EFC-8BDD-8A1641C8D5C2Q38633596-E6CA2EC2-BC4F-43E5-83E7-0B4ED9BEE94DQ38694727-D1666251-D627-4100-BB6A-02CBC57A555DQ38710840-5158A1C7-4F4D-471C-9E52-E17CDB5FB4C6Q38744686-BF040106-5C2F-4137-9BC2-BDC30D09C881Q38790644-37895B3E-AE4C-4738-9B80-F4D02CABFD54Q38822818-BD384A35-BEF6-40EB-B09D-347F7C0543F2Q38844694-B4BD8364-DED6-4536-824F-815B048B20EB
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Affinity and avidity in antibody-based tumor targeting
@ast
Affinity and avidity in antibody-based tumor targeting
@en
Affinity and avidity in antibody-based tumor targeting
@nl
type
label
Affinity and avidity in antibody-based tumor targeting
@ast
Affinity and avidity in antibody-based tumor targeting
@en
Affinity and avidity in antibody-based tumor targeting
@nl
prefLabel
Affinity and avidity in antibody-based tumor targeting
@ast
Affinity and avidity in antibody-based tumor targeting
@en
Affinity and avidity in antibody-based tumor targeting
@nl
P2860
P3181
P356
P1476
Affinity and avidity in antibody-based tumor targeting
@en
P2093
Gregory P Adams
Stephen I Rudnick
P2860
P304
P3181
P356
10.1089/CBR.2009.0627
P407
P577
2009-04-01T00:00:00Z